Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
257
-
Total 13F shares, excl. options
-
84.4M
-
Shares change
-
+3.22M
-
Total reported value, excl. options
-
$1.42B
-
Value change
-
+$63M
-
Put/Call ratio
-
0.59
-
Number of buys
-
103
-
Number of sells
-
-117
-
Price
-
$16.81
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2023
288 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2023.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 257 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84.4M shares
of 123M outstanding shares and own 68.55% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15.8M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (8.89M shares), VANGUARD GROUP INC (7.12M shares), STATE STREET CORP (6.79M shares), DIMENSIONAL FUND ADVISORS LP (2.6M shares), GEODE CAPITAL MANAGEMENT, LLC (2.2M shares), MORGAN STANLEY (1.96M shares), ROYCE & ASSOCIATES LP (1.74M shares), RENAISSANCE TECHNOLOGIES LLC (1.6M shares), and Boston Partners (1.54M shares).
This table shows the top 257 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.